Nanobac enlists Lebanese distributor for Middle East CNP (calcifying nanoparticles) sales:
This article was originally published in Clinica
Executive Summary
Nanobac Pharmaceuticals, the Tampa, Florida-based specialist in nanobacteria-based diagnostics, has appointed Diagnostic Products Corporation Lebanon (DPCL) as its exclusive product distributor for the Middle East region. DPCL will sell Nanobac's CE-marked tests for calcifying nanoparticles (CNPs) in 11 countries, including Lebanon, Saudi Arabia, Syria, Jordan, Iraq, Kuwait, Bahrain and Egypt. The distributor is not affiliated to the US IVD company DPC that is now part of Siemens Medical Solutions Diagnostics. CNPs form a calcium phosphate coating identical to harmful deposits found in diseases such as atherosclerosis, kidney stones, prostatitis, breast cancer and ovarian cancer.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.